Loading…

The regulation of cytochrome P450 2E1 during LPS-induced inflammation in the rat

It is well known that inflammatory and infectious conditions differentially regulate cytochrome P450 (P450)-mediated drug metabolism in the liver. We have previously outlined a potential pathway for the downregulation in hepatic cytochrome P450 following LPS-mediated inflammation in the CNS (Abdulla...

Full description

Saved in:
Bibliographic Details
Published in:Toxicology and applied pharmacology 2006-10, Vol.216 (1), p.1-10
Main Authors: Abdulla, Dalya, Goralski, Kerry B., Renton, Kenneth W.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c509t-526d699530f834b9564bddc17a7e2eb77e4905846db7798c789374dabc5e5eee3
cites
container_end_page 10
container_issue 1
container_start_page 1
container_title Toxicology and applied pharmacology
container_volume 216
creator Abdulla, Dalya
Goralski, Kerry B.
Renton, Kenneth W.
description It is well known that inflammatory and infectious conditions differentially regulate cytochrome P450 (P450)-mediated drug metabolism in the liver. We have previously outlined a potential pathway for the downregulation in hepatic cytochrome P450 following LPS-mediated inflammation in the CNS (Abdulla, D., Goralski, K.B., Garcia Del Busto Cano, E., Renton, K.W., 2005. The signal transduction pathways involved in hepatic cytochrome P450 regulation in the rat during an LPS-induced model of CNS inflammation. Drug Metab. Dispos). The purpose of this study was to outline the effects of LPS-induced peripheral and central nervous system inflammation on hepatic cytochrome P450 2E1 (CYP2E1) in vivo, an enzyme that plays an important role in various physiological and pathological states. We report an increase in hepatic mRNA expression of CYP2E1 that occurred as early as 2–3 h following either the intraperitoneal (i.p.) injection of 5 mg/kg LPS or i.c.v. administration of 25 μg of LPS. This increase in CYP2E1 mRNA expression was sustained for 24 h. In sharp contrast to the increase in hepatic CYP2E1 mRNA, we observed a significant reduction in the catalytic activity of this enzyme 24 h following either the i.c.v. or i.p. administration of LPS. Cycloheximide or actinomycin-D did not change the LPS-mediated downregulation in hepatic CYP2E1 catalytic activity. Our results support the idea that LPS acts at two different levels to regulate hepatic CYP2E1: a transcriptional level to increase CYP2E1 mRNA expression and a post-transcriptional level to regulate CYP2E1 protein and activity.
doi_str_mv 10.1016/j.taap.2006.03.012
format article
fullrecord <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_20850421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041008X06001207</els_id><sourcerecordid>19386278</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-526d699530f834b9564bddc17a7e2eb77e4905846db7798c789374dabc5e5eee3</originalsourceid><addsrcrecordid>eNp9kE2L1EAQhhtR3HH1D3iQgOgtsfojSTd4WZb1AwYccAVvTae7stND0hm7O8L-exMysDdPVYfnfal6CHlLoaJAm0-nKhtzrhhAUwGvgLJnZEdBNSVwzp-THYCgJYD8fUVepXQCACUEfUmuaNNSJhXbkcP9EYuID_Ngsp9CMfWFfcyTPcZpxOIgaijYHS3cHH14KPaHn6UPbrboCh_6wYzjFvOhyGuRya_Ji94MCd9c5jX59eXu_vZbuf_x9fvtzb60Nahc1qxxjVI1h15y0am6EZ1zlramRYZd26JQUEvRuGVX0rZS8VY409kaa0Tk1-T91jul7HWyPqM92ikEtFkzkDUIRhfq40ad4_RnxpT16JPFYTABpzlpqrhsWCsXkG2gjVNKEXt9jn408VFT0KttfdKrbb3a1sD1YnsJvbu0z92I7ily0bsAHy6ASdYMfTTB-vTESQFKgVi4zxuHi7G_HuP6EIZFs4_rP27y_7vjH7Mqmxw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19386278</pqid></control><display><type>article</type><title>The regulation of cytochrome P450 2E1 during LPS-induced inflammation in the rat</title><source>ScienceDirect Freedom Collection</source><creator>Abdulla, Dalya ; Goralski, Kerry B. ; Renton, Kenneth W.</creator><creatorcontrib>Abdulla, Dalya ; Goralski, Kerry B. ; Renton, Kenneth W.</creatorcontrib><description>It is well known that inflammatory and infectious conditions differentially regulate cytochrome P450 (P450)-mediated drug metabolism in the liver. We have previously outlined a potential pathway for the downregulation in hepatic cytochrome P450 following LPS-mediated inflammation in the CNS (Abdulla, D., Goralski, K.B., Garcia Del Busto Cano, E., Renton, K.W., 2005. The signal transduction pathways involved in hepatic cytochrome P450 regulation in the rat during an LPS-induced model of CNS inflammation. Drug Metab. Dispos). The purpose of this study was to outline the effects of LPS-induced peripheral and central nervous system inflammation on hepatic cytochrome P450 2E1 (CYP2E1) in vivo, an enzyme that plays an important role in various physiological and pathological states. We report an increase in hepatic mRNA expression of CYP2E1 that occurred as early as 2–3 h following either the intraperitoneal (i.p.) injection of 5 mg/kg LPS or i.c.v. administration of 25 μg of LPS. This increase in CYP2E1 mRNA expression was sustained for 24 h. In sharp contrast to the increase in hepatic CYP2E1 mRNA, we observed a significant reduction in the catalytic activity of this enzyme 24 h following either the i.c.v. or i.p. administration of LPS. Cycloheximide or actinomycin-D did not change the LPS-mediated downregulation in hepatic CYP2E1 catalytic activity. Our results support the idea that LPS acts at two different levels to regulate hepatic CYP2E1: a transcriptional level to increase CYP2E1 mRNA expression and a post-transcriptional level to regulate CYP2E1 protein and activity.</description><identifier>ISSN: 0041-008X</identifier><identifier>EISSN: 1096-0333</identifier><identifier>DOI: 10.1016/j.taap.2006.03.012</identifier><identifier>PMID: 16712892</identifier><identifier>CODEN: TXAPA9</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; ACTINOMYCIN ; Actinomycin-D ; Animals ; Biological and medical sciences ; Blotting, Northern ; Blotting, Western ; CENTRAL NERVOUS SYSTEM ; CYCLOHEXIMIDE ; Cycloheximide - pharmacology ; CYP2E1 ; Cytochrome P-450 CYP2E1 - genetics ; Cytochrome P-450 CYP2E1 - metabolism ; Cytochrome P-450 CYP2E1 Inhibitors ; Dactinomycin - pharmacology ; Down-Regulation - drug effects ; ENZYMES ; GENE REGULATION ; Hepatocyte Nuclear Factor 1-alpha - antagonists &amp; inhibitors ; Hepatocyte Nuclear Factor 1-alpha - metabolism ; HNF1α ; IN VIVO ; In vivo regulation ; INFLAMMATION ; Inflammation - chemically induced ; Inflammation - genetics ; Inflammation - metabolism ; INJECTION ; Injections, Intraperitoneal ; Injections, Intraventricular ; INTERFERON ; Lipopolysaccharide ; Lipopolysaccharides - administration &amp; dosage ; Lipopolysaccharides - toxicity ; LIVER ; Liver - drug effects ; Liver - enzymology ; Liver - metabolism ; Male ; Medical sciences ; METABOLISM ; Microsomes, Liver - drug effects ; Microsomes, Liver - enzymology ; Microsomes, Liver - metabolism ; Pesticides, fertilizers and other agrochemicals toxicology ; Protein Synthesis Inhibitors - pharmacology ; RATS ; Rats, Sprague-Dawley ; RNA Interference - drug effects ; RNA, Messenger - genetics ; RNA, Messenger - metabolism ; Time Factors ; Toxicology ; Transcription Factor AP-1 - metabolism ; Up-Regulation - drug effects</subject><ispartof>Toxicology and applied pharmacology, 2006-10, Vol.216 (1), p.1-10</ispartof><rights>2006 Elsevier Inc.</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-526d699530f834b9564bddc17a7e2eb77e4905846db7798c789374dabc5e5eee3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18409904$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16712892$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/20850421$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdulla, Dalya</creatorcontrib><creatorcontrib>Goralski, Kerry B.</creatorcontrib><creatorcontrib>Renton, Kenneth W.</creatorcontrib><title>The regulation of cytochrome P450 2E1 during LPS-induced inflammation in the rat</title><title>Toxicology and applied pharmacology</title><addtitle>Toxicol Appl Pharmacol</addtitle><description>It is well known that inflammatory and infectious conditions differentially regulate cytochrome P450 (P450)-mediated drug metabolism in the liver. We have previously outlined a potential pathway for the downregulation in hepatic cytochrome P450 following LPS-mediated inflammation in the CNS (Abdulla, D., Goralski, K.B., Garcia Del Busto Cano, E., Renton, K.W., 2005. The signal transduction pathways involved in hepatic cytochrome P450 regulation in the rat during an LPS-induced model of CNS inflammation. Drug Metab. Dispos). The purpose of this study was to outline the effects of LPS-induced peripheral and central nervous system inflammation on hepatic cytochrome P450 2E1 (CYP2E1) in vivo, an enzyme that plays an important role in various physiological and pathological states. We report an increase in hepatic mRNA expression of CYP2E1 that occurred as early as 2–3 h following either the intraperitoneal (i.p.) injection of 5 mg/kg LPS or i.c.v. administration of 25 μg of LPS. This increase in CYP2E1 mRNA expression was sustained for 24 h. In sharp contrast to the increase in hepatic CYP2E1 mRNA, we observed a significant reduction in the catalytic activity of this enzyme 24 h following either the i.c.v. or i.p. administration of LPS. Cycloheximide or actinomycin-D did not change the LPS-mediated downregulation in hepatic CYP2E1 catalytic activity. Our results support the idea that LPS acts at two different levels to regulate hepatic CYP2E1: a transcriptional level to increase CYP2E1 mRNA expression and a post-transcriptional level to regulate CYP2E1 protein and activity.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>ACTINOMYCIN</subject><subject>Actinomycin-D</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blotting, Northern</subject><subject>Blotting, Western</subject><subject>CENTRAL NERVOUS SYSTEM</subject><subject>CYCLOHEXIMIDE</subject><subject>Cycloheximide - pharmacology</subject><subject>CYP2E1</subject><subject>Cytochrome P-450 CYP2E1 - genetics</subject><subject>Cytochrome P-450 CYP2E1 - metabolism</subject><subject>Cytochrome P-450 CYP2E1 Inhibitors</subject><subject>Dactinomycin - pharmacology</subject><subject>Down-Regulation - drug effects</subject><subject>ENZYMES</subject><subject>GENE REGULATION</subject><subject>Hepatocyte Nuclear Factor 1-alpha - antagonists &amp; inhibitors</subject><subject>Hepatocyte Nuclear Factor 1-alpha - metabolism</subject><subject>HNF1α</subject><subject>IN VIVO</subject><subject>In vivo regulation</subject><subject>INFLAMMATION</subject><subject>Inflammation - chemically induced</subject><subject>Inflammation - genetics</subject><subject>Inflammation - metabolism</subject><subject>INJECTION</subject><subject>Injections, Intraperitoneal</subject><subject>Injections, Intraventricular</subject><subject>INTERFERON</subject><subject>Lipopolysaccharide</subject><subject>Lipopolysaccharides - administration &amp; dosage</subject><subject>Lipopolysaccharides - toxicity</subject><subject>LIVER</subject><subject>Liver - drug effects</subject><subject>Liver - enzymology</subject><subject>Liver - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>METABOLISM</subject><subject>Microsomes, Liver - drug effects</subject><subject>Microsomes, Liver - enzymology</subject><subject>Microsomes, Liver - metabolism</subject><subject>Pesticides, fertilizers and other agrochemicals toxicology</subject><subject>Protein Synthesis Inhibitors - pharmacology</subject><subject>RATS</subject><subject>Rats, Sprague-Dawley</subject><subject>RNA Interference - drug effects</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Messenger - metabolism</subject><subject>Time Factors</subject><subject>Toxicology</subject><subject>Transcription Factor AP-1 - metabolism</subject><subject>Up-Regulation - drug effects</subject><issn>0041-008X</issn><issn>1096-0333</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp9kE2L1EAQhhtR3HH1D3iQgOgtsfojSTd4WZb1AwYccAVvTae7stND0hm7O8L-exMysDdPVYfnfal6CHlLoaJAm0-nKhtzrhhAUwGvgLJnZEdBNSVwzp-THYCgJYD8fUVepXQCACUEfUmuaNNSJhXbkcP9EYuID_Ngsp9CMfWFfcyTPcZpxOIgaijYHS3cHH14KPaHn6UPbrboCh_6wYzjFvOhyGuRya_Ji94MCd9c5jX59eXu_vZbuf_x9fvtzb60Nahc1qxxjVI1h15y0am6EZ1zlramRYZd26JQUEvRuGVX0rZS8VY409kaa0Tk1-T91jul7HWyPqM92ikEtFkzkDUIRhfq40ad4_RnxpT16JPFYTABpzlpqrhsWCsXkG2gjVNKEXt9jn408VFT0KttfdKrbb3a1sD1YnsJvbu0z92I7ily0bsAHy6ASdYMfTTB-vTESQFKgVi4zxuHi7G_HuP6EIZFs4_rP27y_7vjH7Mqmxw</recordid><startdate>20061001</startdate><enddate>20061001</enddate><creator>Abdulla, Dalya</creator><creator>Goralski, Kerry B.</creator><creator>Renton, Kenneth W.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20061001</creationdate><title>The regulation of cytochrome P450 2E1 during LPS-induced inflammation in the rat</title><author>Abdulla, Dalya ; Goralski, Kerry B. ; Renton, Kenneth W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-526d699530f834b9564bddc17a7e2eb77e4905846db7798c789374dabc5e5eee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>ACTINOMYCIN</topic><topic>Actinomycin-D</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blotting, Northern</topic><topic>Blotting, Western</topic><topic>CENTRAL NERVOUS SYSTEM</topic><topic>CYCLOHEXIMIDE</topic><topic>Cycloheximide - pharmacology</topic><topic>CYP2E1</topic><topic>Cytochrome P-450 CYP2E1 - genetics</topic><topic>Cytochrome P-450 CYP2E1 - metabolism</topic><topic>Cytochrome P-450 CYP2E1 Inhibitors</topic><topic>Dactinomycin - pharmacology</topic><topic>Down-Regulation - drug effects</topic><topic>ENZYMES</topic><topic>GENE REGULATION</topic><topic>Hepatocyte Nuclear Factor 1-alpha - antagonists &amp; inhibitors</topic><topic>Hepatocyte Nuclear Factor 1-alpha - metabolism</topic><topic>HNF1α</topic><topic>IN VIVO</topic><topic>In vivo regulation</topic><topic>INFLAMMATION</topic><topic>Inflammation - chemically induced</topic><topic>Inflammation - genetics</topic><topic>Inflammation - metabolism</topic><topic>INJECTION</topic><topic>Injections, Intraperitoneal</topic><topic>Injections, Intraventricular</topic><topic>INTERFERON</topic><topic>Lipopolysaccharide</topic><topic>Lipopolysaccharides - administration &amp; dosage</topic><topic>Lipopolysaccharides - toxicity</topic><topic>LIVER</topic><topic>Liver - drug effects</topic><topic>Liver - enzymology</topic><topic>Liver - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>METABOLISM</topic><topic>Microsomes, Liver - drug effects</topic><topic>Microsomes, Liver - enzymology</topic><topic>Microsomes, Liver - metabolism</topic><topic>Pesticides, fertilizers and other agrochemicals toxicology</topic><topic>Protein Synthesis Inhibitors - pharmacology</topic><topic>RATS</topic><topic>Rats, Sprague-Dawley</topic><topic>RNA Interference - drug effects</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Messenger - metabolism</topic><topic>Time Factors</topic><topic>Toxicology</topic><topic>Transcription Factor AP-1 - metabolism</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdulla, Dalya</creatorcontrib><creatorcontrib>Goralski, Kerry B.</creatorcontrib><creatorcontrib>Renton, Kenneth W.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>Toxicology and applied pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdulla, Dalya</au><au>Goralski, Kerry B.</au><au>Renton, Kenneth W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The regulation of cytochrome P450 2E1 during LPS-induced inflammation in the rat</atitle><jtitle>Toxicology and applied pharmacology</jtitle><addtitle>Toxicol Appl Pharmacol</addtitle><date>2006-10-01</date><risdate>2006</risdate><volume>216</volume><issue>1</issue><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>0041-008X</issn><eissn>1096-0333</eissn><coden>TXAPA9</coden><abstract>It is well known that inflammatory and infectious conditions differentially regulate cytochrome P450 (P450)-mediated drug metabolism in the liver. We have previously outlined a potential pathway for the downregulation in hepatic cytochrome P450 following LPS-mediated inflammation in the CNS (Abdulla, D., Goralski, K.B., Garcia Del Busto Cano, E., Renton, K.W., 2005. The signal transduction pathways involved in hepatic cytochrome P450 regulation in the rat during an LPS-induced model of CNS inflammation. Drug Metab. Dispos). The purpose of this study was to outline the effects of LPS-induced peripheral and central nervous system inflammation on hepatic cytochrome P450 2E1 (CYP2E1) in vivo, an enzyme that plays an important role in various physiological and pathological states. We report an increase in hepatic mRNA expression of CYP2E1 that occurred as early as 2–3 h following either the intraperitoneal (i.p.) injection of 5 mg/kg LPS or i.c.v. administration of 25 μg of LPS. This increase in CYP2E1 mRNA expression was sustained for 24 h. In sharp contrast to the increase in hepatic CYP2E1 mRNA, we observed a significant reduction in the catalytic activity of this enzyme 24 h following either the i.c.v. or i.p. administration of LPS. Cycloheximide or actinomycin-D did not change the LPS-mediated downregulation in hepatic CYP2E1 catalytic activity. Our results support the idea that LPS acts at two different levels to regulate hepatic CYP2E1: a transcriptional level to increase CYP2E1 mRNA expression and a post-transcriptional level to regulate CYP2E1 protein and activity.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>16712892</pmid><doi>10.1016/j.taap.2006.03.012</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-008X
ispartof Toxicology and applied pharmacology, 2006-10, Vol.216 (1), p.1-10
issn 0041-008X
1096-0333
language eng
recordid cdi_osti_scitechconnect_20850421
source ScienceDirect Freedom Collection
subjects 60 APPLIED LIFE SCIENCES
ACTINOMYCIN
Actinomycin-D
Animals
Biological and medical sciences
Blotting, Northern
Blotting, Western
CENTRAL NERVOUS SYSTEM
CYCLOHEXIMIDE
Cycloheximide - pharmacology
CYP2E1
Cytochrome P-450 CYP2E1 - genetics
Cytochrome P-450 CYP2E1 - metabolism
Cytochrome P-450 CYP2E1 Inhibitors
Dactinomycin - pharmacology
Down-Regulation - drug effects
ENZYMES
GENE REGULATION
Hepatocyte Nuclear Factor 1-alpha - antagonists & inhibitors
Hepatocyte Nuclear Factor 1-alpha - metabolism
HNF1α
IN VIVO
In vivo regulation
INFLAMMATION
Inflammation - chemically induced
Inflammation - genetics
Inflammation - metabolism
INJECTION
Injections, Intraperitoneal
Injections, Intraventricular
INTERFERON
Lipopolysaccharide
Lipopolysaccharides - administration & dosage
Lipopolysaccharides - toxicity
LIVER
Liver - drug effects
Liver - enzymology
Liver - metabolism
Male
Medical sciences
METABOLISM
Microsomes, Liver - drug effects
Microsomes, Liver - enzymology
Microsomes, Liver - metabolism
Pesticides, fertilizers and other agrochemicals toxicology
Protein Synthesis Inhibitors - pharmacology
RATS
Rats, Sprague-Dawley
RNA Interference - drug effects
RNA, Messenger - genetics
RNA, Messenger - metabolism
Time Factors
Toxicology
Transcription Factor AP-1 - metabolism
Up-Regulation - drug effects
title The regulation of cytochrome P450 2E1 during LPS-induced inflammation in the rat
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T23%3A08%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20regulation%20of%20cytochrome%20P450%202E1%20during%20LPS-induced%20inflammation%20in%20the%20rat&rft.jtitle=Toxicology%20and%20applied%20pharmacology&rft.au=Abdulla,%20Dalya&rft.date=2006-10-01&rft.volume=216&rft.issue=1&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=0041-008X&rft.eissn=1096-0333&rft.coden=TXAPA9&rft_id=info:doi/10.1016/j.taap.2006.03.012&rft_dat=%3Cproquest_osti_%3E19386278%3C/proquest_osti_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c509t-526d699530f834b9564bddc17a7e2eb77e4905846db7798c789374dabc5e5eee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19386278&rft_id=info:pmid/16712892&rfr_iscdi=true